[Skip to Navigation]
Research Letter
October 19, 2020

Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy

Author Affiliations
  • 1Teva Pharmaceutical Industries Ltd, Netanya, Israel
JAMA Intern Med. 2021;181(2):275-277. doi:10.1001/jamainternmed.2020.4009

Although results of animal studies have shown reproductive toxic effects with use of modafinil and armodafinil, data on exposure during pregnancy in humans are limited.1,2 The US Provigil/Nuvigil Pregnancy Registry, a postmarketing requirement with data annually reported to the US Food and Drug Administration, was established to evaluate pregnancy and fetal outcomes in individuals who could become pregnant and received these drugs during pregnancy. This report provides results from cumulative data as of February 2019.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×